Journal of Bone Oncology最新文献

{"title":"IFC-305, an adenosine derivative, inhibits the osteolytic metastases of triple-negative breast cancer","authors":"Claudia Alcira Espinoza-González ,&nbsp;Citlalli Oyuki Mendoza-Chacón ,&nbsp;Pierrick G.J. Fournier ,&nbsp;Gabriela Velasco-Loyden ,&nbsp;Felipe Olvera ,&nbsp;Victoria Chagoya de Sánchez ,&nbsp;Rafael Vazquez-Duhalt ,&nbsp;Patricia Juárez","doi":"10.1016/j.jbo.2025.100704","DOIUrl":"10.1016/j.jbo.2025.100704","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is an aggressive subtype of cancer characterized by limited therapeutic options and a propensity to form metastasis, particularly to bone. Given the mortality and morbidity linked to TNBC, the advancement of novel and effective therapies is essential. This work studies the potential of an adenosine derivative compound (IFC-305) as a therapeutic agent for breast cancer bone metastasis. It focuses on its effects on bone metastasis, including cell viability, migration, cell cycle, and apoptosis <em>in vitro</em>. <em>In vitro</em> assays demonstrated that IFC-305 significantly reduced TNBC cell viability and migration in a dose-dependent manner. Additionally, it promoted cell cycle arrest and decreased the proportion of cells in the S phase, although it did not induce apoptosis in 4T1 cells. Furthermore, <em>in vivo</em> experiments using a murine model of bone metastasis revealed that treatment with IFC-305 attenuated osteolytic lesions associated with breast cancer metastasis. Importantly, our findings highlight an interaction between this adenosine derivative and the TGF-β signaling pathway. The derivative compound effectively inhibited SMAD2/3 phosphorylation, a key mediator of TGF-β signaling pathway involved in cell growth, differentiation, migration and metastatic progression. Besides, IFC-305 reduced TGF-β regulated PMPEA1 expression, a gene associated with cancer stemness and tumor invasion. These findings provide evidence for the therapeutic potential of the IFC-305 in treating metastatic breast cancer in the bone and warrant further investigation to fully elucidate its mechanism of action and evaluate its clinical translatability.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100704"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of cancer and non-cancer mortality in patients with bone metastases: A population-based study","authors":"Xia Yan ,&nbsp;Hongyu Liu ,&nbsp;Xueqi Bai ,&nbsp;Jin Xu ,&nbsp;Xiaojun Lou ,&nbsp;Lai Wang","doi":"10.1016/j.jbo.2025.100708","DOIUrl":"10.1016/j.jbo.2025.100708","url":null,"abstract":"<div><h3>Purpose</h3><div>To characterize causes of death in patients with bone metastases and to support data-driven approaches to survivorship planning and clinical decision-making in this population.</div></div><div><h3>Methods</h3><div>Using data from the SEER registry (2010–2021), we identified 186,404 patients with newly diagnosed bone metastases. Causes of death were classified as related to the cancer-specific, non-cancer, or subsequent cancer. Standardized mortality ratios (SMRs) were calculated to assess excess non-cancer mortality relative to the general population.</div></div><div><h3>Results</h3><div>During follow-up, 133,393 patients (71.5 %) died from the primary cancer, 11,062 (5.9 %) from non-cancer causes, and 929 (0.5 %) from other malignancies. Although cancer remained the predominant cause of death, non-cancer mortality increased over time (from 6.3 % in 2010 to 9.5 % in 2021). Cardiovascular disease, COPD, and cerebrovascular events were the most common non-cancer causes. The greatest excess mortality was observed for HIV-related infection conditions (SMR: 13.24), septicemia (10.60), suicide (6.68), and pneumonia/influenza (6.04).</div></div><div><h3>Conclusion</h3><div>Non-cancer mortality is an increasingly important contributor to death among patients with bone metastases, underscoring the need for targeted prevention strategies for infections, cardiovascular disease, and other avoidable causes in this vulnerable population.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100708"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144886742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social determinants are associated with clinical presentation of acute pathological fracture in metastatic long-bone disease","authors":"Tom M. de Groot ,&nbsp;Lotte R. van der Linden ,&nbsp;Angad D.S. Bedi ,&nbsp;Andreea A. Lucaciu ,&nbsp;Caleb C. Jang ,&nbsp;Olivier Q. Groot ,&nbsp;Job N. Doornberg ,&nbsp;Paul C. Jutte ,&nbsp;Santiago A. Lozano-Calderon ,&nbsp;J.H. Schwab","doi":"10.1016/j.jbo.2025.100707","DOIUrl":"10.1016/j.jbo.2025.100707","url":null,"abstract":"<div><h3>Background</h3><div>Social Determinants of Health (SDOH) are non-medical factors that influence health, which have gained recognition across medical disciplines. Their impact on survival and disease presentation of patients with metastatic bone disease (MBD) remains unexplored.</div></div><div><h3>Methods</h3><div>This retrospective observational study included 712 undergoing surgery for symptomatic long-bone metastases patients between 2013 and 2022. SDOH were evaluated using Cox Proportional hazards regression for post-operative survival. A multivariate logistic regression analysis was performed to identify associated factors for clinical presentation with a completed pathologic fracture.</div></div><div><h3>Results</h3><div>The median overall survival was 264 days (IQR 74–772). Clinical presentation with a pathologic fracture as the initial symptom of metastatic bone disease (MBD) was observed in 15 % of patients (106/712).</div><div>SDOH factors played a significant role in clinical presentation. Patients with secondary insurance coverage were substantially less likely to present with a pathologic fracture (OR 0.26, 95 % CI 0.14–0.49; p &lt; 0.01). In a sub-analysis of the most common tumors (breast, renal, and lung cancer patients; n = 353), attending college was associated with a significantly lower likelihood of presenting with a pathologic fracture as the initial symptom of metastatic bone disease (OR 0.54, 95 % CI 0.30–0.95; p = 0.03)</div></div><div><h3>Conclusion</h3><div>This study suggests that unfavorable SDOH factors are associated with decreased post-operative survival and a higher likelihood of initial clinical presentation with a completed pathological fracture. Incorporating social determinants into comprehensive care strategies for individuals with MBD may guide targeted interventions and optimize patient management to improve outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100707"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osseous invasion in extremity soft-tissue sarcomas: prevalence, diagnosis, and surgical management- A narrative review","authors":"Seyyed Saeed Khabiri ,&nbsp;Khalil Kargar Shooroki ,&nbsp;Sadegh Saberi ,&nbsp;Hamed Naghizadeh","doi":"10.1016/j.jbo.2025.100712","DOIUrl":"10.1016/j.jbo.2025.100712","url":null,"abstract":"<div><h3>Background</h3><div>Osseous invasion in extremity soft-tissue sarcomas (STS) occurs in approximately 5–11% of cases and is associated with larger tumor size, higher histologic grade, deeper location, and increased risk of metastasis. Despite its relative rarity, bone invasion is a critical prognostic factor, presenting unique diagnostic and surgical challenges.</div></div><div><h3>Purpose</h3><div>This review aimed to synthesize current evidence on the prevalence, diagnostic imaging, surgical management, and prognostic impact of osseous invasion in extremity STS and to offer evidence-based recommendations for clinical practice.</div></div><div><h3>Methods</h3><div>A comprehensive narrative review was conducted using structured searches of PubMed, Embase, and Cochrane Library, focusing on studies reporting original data on extremity STS with bone involvement. The key outcomes included diagnostic accuracy, surgical margins, functional recovery, and survival rates.</div></div><div><h3>Results</h3><div>Bone invasion significantly predicted poorer overall and disease-free survival, with 5-year survival rates of 27–40% compared to 60–70% in non-invasive cases. MRI remains the imaging modality of choice, although standardized radiological criteria for bone invasion are lacking. En-bloc resection provides reliable local control but carries substantial morbidity. Emerging bone-sparing techniques, such as subperiosteal and hemicortical resections, have demonstrated comparable oncologic outcomes with superior functional results in selected patients.</div></div><div><h3>Conclusions</h3><div>Bone invasion in extremity STS represents a high-risk tumor subset that warrants individualized multidisciplinary management. While wide resection remains the standard treatment in cases with medullary involvement, selected patients may benefit from function-preserving approaches without compromising oncologic safety. Future research should focus on standardizing the diagnostic criteria, validating conservative surgical strategies, and refining multimodal treatment protocols to optimize outcomes.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100712"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy for spine and non-spine bone metastases in prostate carcinoma – a multicenter cohort analysis","authors":"Franziska Nägler ,&nbsp;Isabell Seiler ,&nbsp;Sebastian Schäfer ,&nbsp;Johannes Meents ,&nbsp;Fabian Lohaus ,&nbsp;Arne Grün ,&nbsp;Olaf Wittenstein ,&nbsp;Kenneth Klischies ,&nbsp;Julia Remmele ,&nbsp;Alexander Rühle ,&nbsp;Miriam Eckl ,&nbsp;Oliver Blanck ,&nbsp;Judit Boda-Heggemann ,&nbsp;Frank A. Giordano ,&nbsp;Christos Moustakis ,&nbsp;Nils H. Nicolay ,&nbsp;Lena Kästner","doi":"10.1016/j.jbo.2025.100710","DOIUrl":"10.1016/j.jbo.2025.100710","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Metastases-directed radiotherapy plays an increasing role in oligometastatic prostate cancers (OMPC). Here, we investigated the role of stereotactic body radiotherapy (SBRT) for spine and non-spine bone metastases (BoM) from prostate cancer in a large real-world multicenter cohort.</div></div><div><h3>Material and methods</h3><div>This multicenter cohort analysis from five tertiary cancer centers included patient data of spine and non-spine BoM irradiated between 2010 and 2024. Overall survival (OS), progression-free survival (PFS), local recurrence-free survival (LRFS), SBRT target volumes and doses, toxicity, and the role of additional systemic therapies were evaluated retrospectively.</div></div><div><h3>Results</h3><div>231 patients (341 BoM) with median follow-up time of 28.3 months were included. Most common localization were spine (39.3 %), pelvic bone (31.7 %), and ribs (17.9 %). 1- and 5-year PFS for spine BoM were 93.8 % (95 %CI:84.2–97.6 %) and 32.1 % (95 %CI:16.8–44.4 %) and for non-spine BoM 91.7 % (95 %CI:85.1–95.5 %) and 36.6 % (95 %CI:25.8–47.5 %), respectively. 1- and 5-year OS for spine BoM amounted to 94.2 % (95 %CI:85.3–97.8 %) and 69.2 % (95 %CI:50.2–82.2 %) and for non-spine 100 % and 73.3 % (95 %CI:59.1–83.3 %). Older age (p &lt; 0.005) and additional systemic therapies (p = 0.05) were associated with worse OS, older age and larger treatment volumes with worse PFS (p = 0.04). Toxicities were low, with fracture rates of 0.3 % (acute) and 1.2 % (late).</div></div><div><h3>Conclusion</h3><div>Bone SBRT for OMPC is an effective treatment with low toxicity and particularly low fracture rates for both spine and non-spine BoM with no difference in outcome based on the localization. Prospective trials will help to identify the patients benefitting most from this approach and to establish standardized SBRT concepts incorporating systemic treatments.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100710"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgery for osteosarcoma with isolated pulmonary metastases: A SEER-based analysis","authors":"Sheng-Fen Liu","doi":"10.1016/j.jbo.2025.100706","DOIUrl":"10.1016/j.jbo.2025.100706","url":null,"abstract":"<div><h3>Background</h3><div>Osteosarcoma frequently metastasizes to the lungs. The role of surgical intervention in patients with isolated pulmonary metastases and early-stage primary tumors (T1-T2) remains unclear.</div></div><div><h3>Methods</h3><div>Data from the SEER database were used to identify osteosarcoma patients diagnosed with T1-T2 stage disease and isolated lung metastases. Patients were categorized based on whether they underwent surgery for the primary tumor. Propensity score matching (PSM) was applied to reduce baseline differences.</div></div><div><h3>Results</h3><div>Before PSM, surgery was associated with significantly improved overall survival (OS) (median OS: 19.0 vs 7.0 months, P &lt; 0.001). After PSM, a trend toward better OS persisted (median OS: 13.0 vs 9.0 months, P = 0.253), though not statistically significant. Surgery was also associated with lower cancer-related death rates both before and after PSM.</div></div><div><h3>Conclusions</h3><div>Surgical resection of the primary tumor may confer a survival benefit in T1-T2 osteosarcoma patients with isolated pulmonary metastases. These findings support the continued evaluation of surgical strategies in metastatic osteosarcoma and underscore the need for prospective validation.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100706"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic bone disease in proximal femur. Outcome of surgical treatments. − Do we know what to do?","authors":"K. Kilk ,&nbsp;G. Kask ,&nbsp;J. Nieminen ,&nbsp;M.K. Laitinen","doi":"10.1016/j.jbo.2025.100711","DOIUrl":"10.1016/j.jbo.2025.100711","url":null,"abstract":"<div><h3>Background</h3><div>Skeletal metastases related pathological fracture reconstruction methods in proximal femur range from osteosynthesis to tumor prostheses with acetabular reconstruction, depending on lesion size and location. This retrospective study, of 299 patients surgically treated for proximal femur metastases, investigates implant survival, complications, and functional outcomes of various surgical strategies for treating pathological fractures of the proximal femur.</div></div><div><h3>Patients and methods</h3><div>This retrospective study of 299 patients surgically treated for proximal femur metastases, investigates implant survival (Kaplan–Meier), complications, and functional outcomes of different surgical strategies. The chi-test and Mann-Witney <em>U</em> test were used for analysis between groups. The subdistribution Hazard Ratio (SHR) of the role of factors affecting implant survival was calculated using competing risk analysis.</div></div><div><h3>Results</h3><div>Reconstruction methods comprised osteosynthesis (n = 59), hemiarthroplasty (n = 72), total hip replacement (THA) (n = 43), and endoprosthetic replacement (EPR) either with or without acetabular component (n = 125). The precise location and size of the metastases was evaluated. The mean implant survival was 17 months (SD 21.2). Complications occurred in 33 patients, 20 required revision surgery. In prosthesis patients, infections and dislocations were the main complications, while mechanical failure predominated in the osteosynthesis group. Mean implant failure time was 11 months, shortest in THA and osteosynthesis. Functional outcomes in 38 patients showed a mean Oxford Hip Score (OHS) of 33, with no significant differences across methods.</div></div><div><h3>Interpretation</h3><div>Patient survival is a critical factor in selecting the appropriate reconstruction method for trochanteric metastatic lesions. Osteosynthesis is suitable for patients with a limited life expectancy. In cases of metastases involving the head-neck anatomical region, arthroplasty with acetabular reconstruction offers no advantage over hemiarthroplasty. With our data there was no statistical difference in functional outcome between different surgical methods.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100711"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145026898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RGS1 stabilized by METTL3-mediated m6A modification promotes the tumorigenicity and macrophage M2 polarization in osteosarcoma","authors":"Zhizhong Liang ,&nbsp;Yuxia Shi ,&nbsp;Mao Wang ,&nbsp;Liqiang Zhang","doi":"10.1016/j.jbo.2025.100705","DOIUrl":"10.1016/j.jbo.2025.100705","url":null,"abstract":"<div><h3>Background</h3><div>Regulators of G-protein signaling 1 (RGS1) has been reported to be involved in immune cell regulation in many cancer types. However, the specific role and mechanism in osteosarcoma (OS) progression and macrophage activation remain unclear.</div></div><div><h3>Methods</h3><div>Levels of mRNA and protein were examined using qRT-PCR and western blotting. Transwell assay, wound healing assay, EdU assay and flow cytometry were used to investigate OS cell invasion, migration, proliferation and apoptosis. Xenografts in mice were established for in vivo assay. Macrophage M2 polarization was evaluated by detecting CD206 + macrophages by flow cytometry. ELISA analysis detected IL-6 and TGF-β1 levels. Methylated RNA immunoprecipitation assay was applied to explore the specific binding of RGS1 and METTL3 (methyltransferase-like 3).</div></div><div><h3>Results</h3><div>RGS1 was highly expressed in OS tissues and cells. The silencing of RGS1 suppressed OS cell invasion, migration, growth and impaired immune response by inhibiting macrophage M2 polarization and M2 macrophage-mediated release of IL-10 and TGF-β1. Mechanistically, METTL3 promoted RGS1 m6A modification and stabilized its expression. METTL3 deficiency also inhibited OS cell invasion, migration, growth and macrophage M2 polarization, while these effects could be abolished by RGS1 overexpression. Besides that, IL–10 elevation induced by M2 macrophages promoted OS cell oncogenic phenotypes.</div></div><div><h3>Conclusion</h3><div>METTL3 stabilized RGS1 mRNA in an m6A-dependent manner to promote the tumorigenicity and macrophage M2 polarization in osteosarcoma, suggesting a novel insight into the therapy of osteosarcoma.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"54 ","pages":"Article 100705"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144781766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteofibrous dysplasia, osteofibrous Dysplasia-Like adamantinoma, and adamantinoma: A Single-center retrospective analysis","authors":"Wei Chen ,&nbsp;Qinglin Jin ,&nbsp;Shaohua Du ,&nbsp;Shuangwu Dai ,&nbsp;Changhe Hou ,&nbsp;Zixiong Lei ,&nbsp;Lin Zhong ,&nbsp;Qingzhu Wei ,&nbsp;Haomiao Li","doi":"10.1016/j.jbo.2025.100700","DOIUrl":"10.1016/j.jbo.2025.100700","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to comprehensively investigate and contrast the imaging manifestations, pathological features, surgical interventions, and prognostic outcomes of <strong>Osteofibrous Dysplasia(OFD)</strong>, <strong>Osteofibrous Dysplasia-Like Adamantinoma(OFD-AD)</strong>, and <strong>Adamantinoma(AD)</strong>. By synthesizing disease profiles and exploring their evolutionary relationships, we sought to identify more effective diagnostic and therapeutic strategies for these conditions.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on patients diagnosed with OFD, OFD-AD, or AD at our institution between 2015 and 2022. The analysis included a detailed comparison of clinical presentations, imaging findings, and pathological characteristics. We also evaluated the impact of different diagnostic and treatment modalities on patient prognosis and explored potential disease evolution and transformation patterns.</div></div><div><h3>Results</h3><div>Fifty patients were included in this study: 16 with OFD, 27 with OFD-AD, and 7 with AD. The median age of onset was 14 years for OFD, 6 years for OFD-AD, and 33 years for AD. All diagnoses were confirmed through a combination of clinical evaluation, imaging (X-rays and MRI), and pathological examination. Among the patients, 2 (both with OFD-AD) were managed with observation only. Thirty-seven patients underwent intralesional resection (16 OFD, 20 OFD-AD, and 1 AD), and 11 patients had complete resection (5 OFD-AD and 6 AD). After a minimum follow-up of 24 months (range: 24–––90 months, median: 56 months), 12 patients experienced tumor recurrence (OFD: 2/16, 12.5 %; OFD-AD: 9/25, 36 %; AD: 1/6, 17 %). One patient had concurrent OFD-AD in the fibula and AD in the tibia. In another case, an OFD-AD recurrence 4 years after surgery was later diagnosed as OFD, and an OFD recurrence 2 years after surgery was reclassified as OFD-AD. No distant metastases were observed in any patient.</div></div><div><h3>Conclusion</h3><div>OFD, OFD-AD, and AD exhibit similarities in clinical and imaging presentations, and their pathological features may represent different stages of a common lesion’s evolution. These diseases have distinct age − related onset patterns and variable recurrence risks. Thus, accurate diagnosis and personalized treatment strategies based on patient characteristics are crucial for effective disease management.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"53 ","pages":"Article 100700"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of treatment delay of multiple myeloma bone disease on later myeloma-related skeletal events and outcome","authors":"Eskelinen Veera ,&nbsp;Niemi Pauli ,&nbsp;Partanen Anu ,&nbsp;Kangas Jaakko ,&nbsp;E.L.Kuusisto Milla","doi":"10.1016/j.jbo.2025.100693","DOIUrl":"10.1016/j.jbo.2025.100693","url":null,"abstract":"<div><div>Limited data exists on the effect of treatment delay of multiple myeloma (MM) bone disease on the disease course. In this real-world analysis of 625 patients with newly diagnosed MM (NDMM) we aimed to investigate the impact of delay in starting bone disease treatment on later skeletal events and outcome.</div><div>Altogether 480 (76.8 %) patients had bone disease at the diagnosis, 282 (45.1 %) patients had a fracture at diagnosis, and 181 (29.1 %) patients had a later fracture during the follow-up. A delay in the initiation of treatment of bone disease was experienced by 221 (35.4 %) patients and tooth extraction was a main reason for the delay. Patients with a delay seemed to experience earlier and more frequent later fractures. Also, a fracture (p = 0.003) or bone disease (p &lt; 0.001) at diagnosis predicted earlier incidence of later fractures. As a bone targeted treatment, altogether 363 (58.1 %) patients received zoledronic acid, 81 (13.0 %) denosumab and 134 (21.4 %) other bone-targeted treatment. Patients treated with denosumab had poorer overall survival (OS) (p &lt; 0.001) and experienced earlier later fractures (p = 0.003). Multivariate analysis showed that bone disease at diagnosis (p = 0.043) and given bone disease treatment (p = 0.023) significantly impacted on the time to next fracture. Regarding OS, delay in osteoprotective treatment (p = 0.004) and time of the diagnosis (p &lt; 0.001) were significant factors in multivariate analysis.</div><div>To conclude, this study suggests that early initiation of bone disease treatment seemed to prevent later fractures. These findings highlight the importance of patients’ rapid access to a dentist and the start of bone targeted treatment without delay after a myeloma diagnosis.</div></div>","PeriodicalId":48806,"journal":{"name":"Journal of Bone Oncology","volume":"53 ","pages":"Article 100693"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}